Targovax has the cheapest oncolytic virus on the marketONCOS-102 is one of the most promising oncolytic viruses with >200 patients treated.
Targovax stock has been under pressure for years after equity offerings at fairly low pricing, but has been making a strong move recently, quite without many investors taking notice.
Norwegian Biotech especially in the field of cancer immunotherapy may be ready for a new round of interest after the recent news about Vaccibody partnering with Genentech.
